Immuron (IMRN) Asset Writedowns and Impairment (2020 - 2023)
Immuron (IMRN) posted quarterly Asset Writedowns and Impairment of $13496.7 for Q2 2023, up 116.95% year-on-year from $6221.1 in Q2 2022, and up 116.95% on a QoQ basis from $6221.1 in Q2 2022.
Immuron (IMRN) Asset Writedowns and Impairment (2020 - 2023) Analysis & Trends
Immuron (IMRN) has reported Asset Writedowns and Impairment for 4 consecutive years, with $13496.7 the latest figure, recorded in Q2 2023.
- Quarterly Asset Writedowns and Impairment rose 116.95% year-over-year to $13496.7 in Q2 2023, while the trailing twelve-month figure through Jun 2023 was -$4326.3 (changed N/A YoY) and the FY2023 annual result came in at $13496.7, up 116.95% from the prior year.
- Asset Writedowns and Impairment climbed to $13496.7 in Q2 2023 per IMRN's latest filing, from $6221.1 in the prior quarter.
- Over the last five years, Asset Writedowns and Impairment for IMRN reached as high as $13496.7 in Q2 2023 and fell as low as -$21225.6 in Q2 2021.
- A 4-year average of -$1081.6 and a median of $1701.3 in 2020 frame the typical range for Asset Writedowns and Impairment.
- Annual changes were most pronounced in 2021 — Asset Writedowns and Impairment slumped 653.07% — and 2022, when it surged 129.31%.
- Year by year, Asset Writedowns and Impairment stood at -$2818.5 in 2020, then sank by 653.07% to -$21225.6 in 2021, then jumped by 129.31% to $6221.1 in 2022, then jumped by 116.95% to $13496.7 in 2023.
- According to Business Quant data, Asset Writedowns and Impairment over the past three periods registered $13496.7, $6221.1, and -$21225.6 for Q2 2023, Q2 2022, and Q2 2021 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,725.60 Bn | 68,725.31 Bn | - |
| 2 | Nanobiotix | 1,953.19 Bn | 1,953.13 Bn | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - |
| 4 | BeOne Medicines | 472.73 Bn | 467.94 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 123.52 Bn | 116.27 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.74 Bn | 60.99 Bn | 3.31 Bn |
| 7 | Belite Bio | 63.09 Bn | 63.09 Bn | - |
| 8 | Argenx Se | 56.42 Bn | 51.24 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.76 Bn | 37.76 Bn | - |
| 10 | Immuron | 258.65 Mn | -28.05 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 13,496.66 |
| Jun 30, 2023 | 13,496.66 |
| Jun 30, 2022 | 6,221.13 |
| Jun 30, 2022 | 6,221.13 |
| Jun 30, 2021 | -21,225.58 |
| Jun 30, 2021 | -21,225.58 |
| Jun 30, 2020 | -2,818.54 |
| Jun 30, 2020 | -2,818.54 |